Cutaneous Human papillomaviruses (HPV) have been associated with squamous cell carcinoma (SCC) in case-control studies, but there is limited data from prospective studies assessing whether virus exposure is able to predict risk for future cancer development. Two major biobanks, the Southern Sweden Microbiology Biobank and the Janus Biobank in Norway, containing samples from 850,000 donors, were followed-up for incident skin cancer for up to 30 years using registry linkages. Altogether 2,623 donors with samples taken before diagnosis of SCC or basal cell carcinoma (BCC) of the skin were identified. Prediagnostic samples and samples from 2,623 matched controls were tested for antibodies against 33 HPV types. Baseline seropositivity to HPV types in genus beta species 2 was associated with SCC risk (OR 1.3, 95% CI: 1.1, 1.7), also for samples taken >18 years before diagnosis (OR 1.8, 95% CI: 1.1, 2.8). Type-specific persistent seropositivity had elevated point estimates of risk for SCC for 29 types and decreased point estimates for only three types. After multiple hypothesis adjustment, HPV 76 was significantly associated with SCC risk and HPV 9 with BCC risk. In summary, seropositivity to certain HPV types were associated with an increased risk for future development of SCC and BCC.
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Human Papillomaviruses (HPVs) belonging to the beta, gamma, mu and nu genera (1) infect healthy skin (2, 3, 4) and are commonly found in non-melanoma skin cancers (NMSC) (5, 6, 7, 8) , including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). In casecontrol studies, HPV of genus beta (7) , genus beta species 2 (5, 8, 9) , genus beta species 1 (6, 10) and the genus gamma (9) have been reported to associate with SCC, whereas not with BCC (5, 6, 10, 11) . HPV types 5 (10) , 8 and 38 (12) have also been reported in SCC. These studies have tested biopsies (5) , plucked hair (7) , archival tissue (6) , swab samples (13) , plasma (10) , and serum (7, 11) and results of HPV analyses may vary depending on the sample tested (13, 14, 15) and the HPV test used (5, 7, 8, 16) .
Ultraviolet (UV)-radiation is an established risk factor for NMSC (17) . As HPV infection is more common on skin sites not covered by clothing (sun-exposed skin) (5, 10) , confounding by UV light is possible. However, sunlight intensity does not affect HPV prevalence (2, 3) and adjustment for UV light does not affect associations between HPV and NMSC [14] .
Prospective studies assessing whether exposure predicts future cancer risk are essential for causality inference. In studies using samples taken at or after diagnosis, the disease may have caused increased susceptibility or reactivation of HPV (reverse causality). Comparison of HPV seroprevalences before or after NMSC diagnosis found that many HPVs had higher seroprevalences in postdiagnostic than in prediagnostic samples (18) . The association of common skin bacteria with NMSC in case-control studies also indicates that reverse causality must be considered as a possible pitfall in studies aiming to elucidate the etiology of NMSC (19) .
Seropositivity for ano-genital HPVs is a marker of past or present infection (20) and prospective HPV seroepidemiology has been instrumental in providing prospective evidence supporting the causal association between HPV and cervical, anogenital and oropharyngeal cancers (20) . High-throughput serology for a multitude of HPV types has been established (21) . Although the performance of cutaneous HPV serology as a marker of skin HPV infection is not entirely clear (11, 18) , the methodology has been useful in discovery of associations of HPV and disease (9, 10, 12) .
Because our previous case-control study had found that HPV of genus beta species 2 were associated with SCC (5), we wished to follow up by performing a prospective serological study of future SCC risk in relation to baseline presence of antibodies to HPV in genus beta species 2. We also explored the risk for SCC or BCC in relation to presence of prediagnostic antibodies to 33 individual HPV types.
MATERIALS AND METHODS
The study adhered to the Declaration of Helsinki and was approved by the Ethical Review Boards (ERB) at the Oslo University, Norway and Lund University, Sweden. For the Norwegian cohort, all 332,000 participants had signed a written informed consent at enrolment and the ERB decided that a renewed consent was not required at follow-up. In Sweden, the ERB decided that an "opt-out" method for consent should be used. The ERB decided that the information about the study should be given to the 524,000 subjects in the cohort by publishing an advertisement in the major newspaper of the population with clear instructions on how to decline and thus not be included in the study.
Cohorts
About 332,000 Norwegian volunteers donated about 493,000 serum samples to the Janus biobank, from 1972 and onwards. Population-registry-based invitations all over Norway enrolled most donors (90%), the remainder being blood donors (22, 23) . Norway has about 4.8 million inhabitants.
About 524,000 individuals donated about 1.5 million serum samples to the Southern Sweden Microbiology Biobank (SSMB), which has a catchment area population of about 1 million inhabitants, from 1969 and onwards (22) . The reasons for donating samples (e.g. microbiological screening of blood donors and of pregnant women) define sub-cohorts that are used when matching controls to the cases, to minimise biases by reason for donating sample. Similarly, the blood donor sub-cohort and the population-registry-based sub-cohort in the Janus Biobank are also used in matching.
Study design
The biobanks were followed-up using linkages to the national cancer registries in Norway and Sweden using the ICD7 code 191 for SCC and ICD7 code 189 for BCC. Cancer registration of NMSC is essentially complete for Norway (24) . For Sweden, only SCC is registered. Cases had at least 1 serum sample taken at least 1 month before diagnosis. For each case, 1 control (alive and free of SCC or BCC (when known) when the case was diagnosed) was selected matched for age at first serum sampling (+/-two years), sex, county (in the Janus Biobank), sub-cohort, number of serial samples and length of follow-up. The first (oldest) sample for the control was matched with the first (oldest) sample of the case for date of sampling (+/-two months). If controls meeting matching criteria could not be found, matching criteria were widened in successive steps of +/-one month of sampling date and +/one year of age until a control was found. No samples taken after diagnosis were included.
The cancer registry linkage of the Janus biobank identified 497 eligible SCC cases and matched controls with 1,550 samples. When NMSC was diagnosed several times, only the first diagnosis was included. Forty-eight cases and controls were excluded from the SCC group and included as BCC, because of a BCC diagnosis preceding the SCC diagnosis.
Conversely, 15 cases and controls from the BCC group were included as SCC because of an SCC diagnosis preceding the BCC diagnosis ( Figure 1) . Review of the different data sources obtained by the cancer registry (clinical reports, histopathology reports and death certificates)
found two BCC cases previously diagnosed as SCC and four SCC cases previously diagnosed as BCC ( Figure 1 ). Five cases and controls were excluded because the first sample of the case or control was donated after the diagnosis of the case (Figure 1 ). Fourteen serial samples were deleted because they were donated after the first NMSC diagnosis of the case. Four cases were re-diagnosed by the cancer registry as non-malignant and excluded ( Figure 1 ). Eightyeight cases diagnosed with non-melanoma skin cancers other than BCC and SCC were excluded as well as 16 cases of connective tissue tumours. Finally, 1,056 samples from 353 SCC cases, and the same number of controls, were included.
The Janus biobank identified 5,073 eligible BCC cases and selected 2,000 of these at random (2,000 cases was sufficient power for detection of an OR of 1.5 with 80% power for individual HPV types and OR of 1.3 with 80% power for species groups, both with a significance level of 0.05). Fifty extra cases were selected in case of missing samples and six of those were used. One sample was excluded since it lacked controls and one sample was handled incorrectly (Figure 1 ). Thirty-nine cases and controls (92 samples) were excluded because the first NMSC diagnosis was before the first sampling ( Figure 1 ). Twenty-two serial samples were excluded because they were donated after the first NMSC diagnosis of the case.
Re-diagnosed cases and cases with different first and last diagnosis mentioned for SCC resulted in exclusion of 19 and addition of 50 cases and controls ( Figure 1 ). Finally, 6,145 samples from 1,990 BCC cases and the same number of controls were included.
The Swedish Cancer Registry has only recently registered BCC and no BCC cases were included from Sweden. The cancer registry linkage identified 419 SCC cases in SSMB. Fiftysix cases and controls had a missing or too low volume sample. Two cases and controls were excluded because the control had had SCC before the case, two were excluded because of incorrect handling, one case and control were excluded because the first sample was not available and matching with the second sample was not possible (Figure 1 ). One case and control were excluded because the control donated the first sample after diagnosis of the case ( Figure 1 ). Seventy-seven cases registered under ICD7 191 or 189 that had diagnoses other than BCC or SCC (e.g., Kaposi´s sarcoma) were excluded. Finally, 280 SCC cases and the same number of controls were included from SSMB (2,059 samples).
Altogether the study contained 9,260 samples (3,115 samples from 633 SCC cases and the same number of controls, and 6,145 samples from 1,990 BCC cases and the same number of controls). In the serial samples analysis, there were 531 BCC cases and 256 SCC cases (and the same number of controls) that had at least 2 prediagnostic samples.
For the Swedish cases and controls life-time cumulative UV exposure was calculated using the yearly UV exposure at the locations where the subjects had resided, from birth until the cases were diagnosed. Information on the lifetime residential addresses down to the Zip-code level was retrieved from the Swedish Tax Agency and information on the yearly UV-index of those locations (as Commission Internationale de l'Éclairage weighted UV-radiation) was retrieved from the Swedish Meteorological and Hydrological Institute.
Serology
We tested for antibodies to the L1 protein of mucosal HPV types HPV 32 (genus alpha species 1) and HPV 13 (genus alpha species 10) and cutaneous HPV types HPV 3, 10 and 77 (genus alpha species 2), HPV 2 and 27 (genus alpha species 4), HPV 7 (genus alpha species 8), , HPV 5, 8, 20, 24 and 36 (genus beta species 1), HPV 9, 15, 17, 23 and 38 (genus beta species 2), HPV 49, 75 and 76 (genus beta species 3), HPV 92 (genus beta species 4), HPV 96 (genus beta species 5), HPV 4, 48, 50, 65 and 95 (genus gamma), HPV 1 and 63 (genus mu), HPV 41 (genus nu) as well as for the so far ungrouped types HPV 101 and 103. As specificity control, we also tested for antibodies against the VP1 protein of the JC virus.
Antibody detection used multiplexed glutathione S-transferase (GST) capture ELISA in combination with fluorescent bead-based Luminex technology (21, 25, 26) . The method has been found to have good reproducibility (10, 21) All serological testing was performed with the analysing laboratory blinded to any information about the samples.
Statistical methods
Relative risks estimated as odds ratios (OR) and 95% confidence intervals (CI) were estimated by conditional logistic regression with SAS 9.1 software (SAS Institute Inc., Cary, NC). If the asymptotic model did not converge, conditional maximum likelihood estimates of ORs were estimated by exact conditional logistic regression with LogXact 8 (Cytel Inc., Cambridge, MA). Heterogeneity in the OR estimates was assessed with a likelihood ratio test.
The raw data for multiple test adjustment consisted of 33 HPV type-specific p-values related to likelihood ratio test for adding the HPV variable with two or four categories to null model. The adjusted p-values were calculated controlling familywise error rate by the Holm method (27) .
RESULTS
There were 432 males and 201 female SCC cases and 1,136 males and 854 female BCC cases.
Distributions of age at first serum sampling are presented in table 1. SCC cases in SSMB are older compared to SCC case in Janus, because enrolment to the Janus biobank generally targeted younger subjects than the SSMB. Baseline seropositivity for an HPV type in genus beta species 2 (HPV 9, 15, 17, 23 or 38) was associated with an increased risk for development of SCC (OR 1.3, 95% CI: 1.1, 1.7) ( Table   2 ). HPV type-specific seropositivity was not significantly associated with SCC risk for any of the 33 investigated HPV types ( Table 2 ). Four HPV types had point estimates of OR below unity, whereas 25 HPV types had OR estimates above unity.
Baseline type-specific HPV seropositivity associated with BCC for only 1/33 HPV types (Table 2 ). Ten HPV types had point estimates of OR below unity, whereas 14 HPV types had OR estimates above unity.
For 30/33 HPV types, seroprevalences were slightly higher for SCC cases than for BCC cases ( (Table 3 ) and acquired seropositivity (seroconversion) was also associated with significantly increased SCC risk for only 1/33 tested HPV types (Table 3) .
Seropositivity at baseline regardless of serostatus at later time points found increased SCC risks for HPV 2, 23 and 95 ( Table 3 ).
The BCC risk among subjects with at least two samples was increased if persistent seropositive for only 1/33 tested HPV types (Table 4 ). Previous (lost) seropositivity was also associated with BCC for only 1/33 HPV types (Table 4 ). Acquired seropositivity was associated with significantly increased BCC risk for three HPV types and with significantly decreased BCC risk for two HPV types (Table 4 ). For persistent seropositivity, ten types had OR estimates suggesting decreased BCC risk and 17 had ORs suggesting increased risk.
Seropositivity at baseline regardless of serostatus at later time points found significantly increased BCC risks for HPV 15 and 95 (Table 4 ).
Adjustment for multiple comparisons for the 33 different HPV types, using a variable with 4 categories each, found that HPV76 was significantly associated with SCC and HPV9 associated with BCC, even after multiple testing adjustment.
Adjustment for UV-exposure was possible for the Swedish subjects, but had no effect on the results. Life-time cumulative sun-exposure could be reconstituted for 272 case-control pairs, with 95 pairs in the group with lowest UV-exposure, 106 in the medium group and 71 individuals in the group with highest UV-exposure (mean life-time UV-exposure for the cases in these groups was 9,938 mW/m 2 , 1,0416 mW/m 2 and 1,0521 mW/m 2 respectively).
The effect of the time between the date of sampling until diagnosis was analysed for SCC for HPV 3, 38 (Table 5 ) and genus beta species 2 and for BCC for HPV 15 and genus beta species 2 (Table 6 ). These types were selected for analysis since they showed significant or nearly significant results in the analyses based on all samples ( Table 2) . Seropositivity for HPV genus beta species 2 in samples taken more than 18 years prior to diagnosis was significantly associated with SCC risk (OR 1.8, 95% CI: 1.1, 2.8). Seropositivity for HPV 3 was associated with increased SCC risk in samples taken more than eight years prior to diagnosis (OR 2.0, 95% CI:1.1, 3.6) ( Table 5 ). For BCC, an association of borderline significance was seen in the intermediate lag time group for HPV genus beta species 2 and for HPV 15 (Table 6 ).
DISCUSSION
Our most consistent finding was the increased risk for future SCC associated with seropositivity for HPV genus beta species 2. The association was seen in analysis of all baseline samples, in analysis restricted to samples taken >18 years before diagnosis and in analysis restricted to subjects with persistent seropositivity and was also a pre-specified hypothesis, as both we and others had previously found an association of HPV genus beta species 2 with SCC, both in studies based on serological testing (9, 10) and on HPV DNA testing of tumour biopsies (5, 8) Our prospective study design is particularly useful for addressing concerns about reverse causality. This concern is particularly relevant for skin cancer, as it has been shown that HPV seroprevalences increase in samples taken after diagnosis (18) suggesting that virus reactivation or increased susceptibility caused by the disease process could explain associations seen. However, an association with risk of cancer diagnosed >18 years later is unlikely to be attributable to reverse causality. Because cases and controls were derived from the same cohorts, followed using nationwide population-based cancer registries, the risk for selection biases is minimised. Additional strengths include sufficient study size to have statistical power to detect also weak associations and that this is the so far only study that, to our knowledge, has analysed NMSC risk in relation to persistence of HPV seropositivity in serial samples. We have looked at serum samples as seroconversion shows that presence of HPV is not merely contamination, i.e. it is evidence of an infection.
High throughput multiplexed GST-L1 serology allowed a comprehensive analysis of a broad spectrum of cutaneous HPV types. As all analyses were performed simultaneously comparability of results is ensured. However, serology for cutaneous HPV types is not as well validated as the serology for ano-genital HPV types (17) . In particular, some cutaneous HPV types appear to have several serotypes (28) and studies correlating seroprevalences with presence of HPV DNA in the same subjects have found associations on the genus/species level rather than on the HPV type level (11) . The possibility that some of the HPV seropositivities investigated may be attributed to cross-reactions with related HPVs therefore needs to be borne in mind.
Although we had access to near-complete data on life-time domiciles as well as to UV light exposure at the zip code level in Sweden and although we found essentially no difference in risk estimates when adjusting for UV exposure, we cannot exclude confounding by UV light as the differences in average UV-exposure among the study participants were small and individual activities (e.g. outdoor sports and profession) might be more important determinants of UV exposure than place of residence. In Norway, place of residence (county) was included in the matching suggesting that average UV light exposure was controlled for.
HPV-type specific persistence of antibodies had a point estimate of SCC risk that was above unity for almost all the HPV types, suggesting that most cutaneous HPV types might confer a weakly increased risk for SCC. If so, the significant risk associated with genus beta species 2 might be attributable to improved statistical power when analysing several HPV types together. It is also possible that only some HPV types associate with SCC and that the tendencies for increased risk seen for related HPV types may be attributable to serological cross-reactivity. The point estimates for the specificity control, the unrelated JC virus, were close to unity in all analyses. The association between SCC and persistent seropositivity for HPV 76 is noteworthy, because a highly increased OR in case of persistence and decreased OR in case of clearance is the biologically expected pattern. This association remained significant also after controlling for multiple testing.
Our analysis of acquired seropositivity and lost seropositivity in relation to SCC risk are consistent with chance findings, although we note that the types with marginally significant associations (HPV 38 and 8) have transforming characteristics (29, 30, 31, 32) and that some (but not all (9)) previous studies have also suggested an NMSC association (12) .
Chance is also a possible explanation for the few and weak associations seen between HPV and BCC risk, but for HPV 9 the risk increase was significant also after adjusting for multiple testing. Contrary to the association between genus beta species 2 and SCC, where multiple previous studies had pointed to an association, the HPV types with marginally significant associations with BCC in some of the analyses (HPV 15, 9 and 95) have not been reported to associate with BCC before. HPV seroprevalences were consistently slightly higher in SCC than in BCC (consistent with previous reports (11) ), also suggesting that cutaneous HPVs associate with SCC rather than with BCC.
In conclusion, seropositivity for HPV in the genus beta species 2 was consistently associated with a long-term future risk for development of SCC. Future studies of how this biomarker is related to the natural history of cutaneous HPV infections could lead to important insights into the aetiology of SCC. 
